The AIM-HN and SEQ-HN study: A pivotal study evaluating the efficacy of tipifarnib in patients with head and neck squamous cell carcinoma (HNSCC) with HRAS mutations (AIM-HN) and the impact of HRAS mutations on response to first line systemic therapies for HNSCC (SEQ-HN) Meeting Abstract
| Authors: | Haddad, R. I.; Harrington, K. J.; Licitra, L. F.; Psyrri, A.; Saba, N. F.; Rajicic, N.; Balsara, B.; Kurman, M. R.; Scholz, C. R.; Gualberto, A.; Ho, A. L. |
| Abstract Title: | The AIM-HN and SEQ-HN study: A pivotal study evaluating the efficacy of tipifarnib in patients with head and neck squamous cell carcinoma (HNSCC) with HRAS mutations (AIM-HN) and the impact of HRAS mutations on response to first line systemic therapies for HNSCC (SEQ-HN) |
| Meeting Title: | 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2020 May 29-31 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-05-20 |
| Language: | English |
| ACCESSION: | WOS:000560368309206 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.15_suppl.TPS6593 |
| Notes: | Meeting Abstract: TPS6593 -- Source: Wos |
